Pharmacotherapy of dilated cardiomyopathy

Area of Science:

• Cardiology
• Pharmacology

Background:

• Dilated cardiomyopathy treatment shares principles with heart failure management.
• The goal is to slow disease progression and enhance patient survival and quality of life.

Purpose of the Study:

• To outline current pharmacological strategies for dilated cardiomyopathy.
• To review established and emerging treatments for heart failure in this context.

Main Methods:

• Review of established treatment guidelines for heart failure.
• Discussion of pharmacological agents including ACE inhibitors, ARBs, beta blockers, and others.
• Evaluation of recent and investigational therapies.

Main Results:

• Angiotensin converting enzyme inhibitors and beta blockers are foundational for all patients.
• Diuretics and mineralocorticoid receptor antagonists are indicated for symptomatic heart failure (NYHA II-IV).
• Specific agents like digoxin, ivabradine, and short-term inotropes are used in particular clinical scenarios. Investigational drugs like rolofylline showed disappointing results, while omecamtiv mecarbil shows future potential.

Conclusions:

• Standard therapy involves ACE inhibitors/ARBs and beta blockers, with diuretics and MRAs for symptomatic patients.
• Treatment is tailored based on heart failure severity and specific patient factors like heart rhythm and heart rate.
• Ongoing research into novel agents like omecamtiv mecarbil may offer future therapeutic options.